Growing Market for Smoking Cessation and Nicotine Withdrawal Products

Jul.19.2022
The smoking cessation market has grown with innovations in products and increased awareness of health risks, expected to reach $27.84 billion by 2031.

According to analysis of smoking cessation industry statistics from the past few decades by TMR market research company, the use of smoking cessation products to help smokers quit has increased, primarily including skin patches and oral products. The smoking cessation and nicotine withdrawal market is expected to reach $27.84 billion by 2031. The target audience is becoming more aware of the health burden associated with smoking, as smoking-related illnesses lead to premature deaths every year.


Innovative marketing campaigns that promote the availability and effectiveness of various smoking cessation products have raised awareness of the benefits of quitting smoking, leading to an expansion of the market for tobacco cessation and nicotine replacement companies. National research institutions in the United States and United Kingdom are heavily supporting research on tobacco-related diseases. Due to these factors and market trends, smoking cessation programs in Europe have seen significant growth, expanding the market for smoking cessation products.


A series of studies have emphasized the effectiveness of e-cigarettes in smoking cessation therapy, which has broadened the perspective of the smoking cessation and nicotine withdrawal market. Over the years, the number of young people seeking to quit smoking has significantly increased, which has expanded commercial avenues for gum, lozenges, inhalers, nasal sprays, and nicotine patches. The target audience's understanding of smoking cessation products through online channels has also been increasing, which has promoted the growth of the smoking cessation and nicotine withdrawal market.


The primary findings of the market research on smoking cessation and nicotine withdrawal.


Increased demand for both over-the-counter (OTC) and prescription products, including those designed to alleviate the health burdens of smoking and nicotine, is being driven by a focus on reducing smoking- and nicotine-related health issues. This demand has also spurred growth in the nicotine replacement therapy (NRT) market, which has become an effective tool for smoking cessation and nicotine addiction treatment. Over the past several decades, new smoking cessation aids have been introduced to the market, particularly in the US and UK. Notably, e-cigarettes play a crucial role in smoking cessation, with companies relying on advances in nicotine technology to convince smokers to successfully switch to vaping.


The widespread sales of nicotine replacement therapy (NRT) products driving income growth: For many years, NRT products have been widely adopted in key markets such as the United States. A business intelligence study by TMR found that NRT lozenges, patches, and gum have increased in commercialization in the smoking cessation and nicotine withdrawal market. Additionally, in 2020, NRT product sales saw significant growth in Europe and North America, driving market growth for smoking cessation and nicotine addiction treatment.


Smoking and Nicotine Cessation Market: Key Drivers


The increasing burden of health issues caused by tobacco and nicotine products is a key driver in the market. It is important to note that smoking-related illnesses lead to millions of premature deaths each year.


Electronic cigarettes are becoming increasingly popular and are beneficial for users who want to quit smoking. Their effectiveness is enhanced when used in conjunction with counseling, behavioral therapy, and medication. There is a growing market for smoking cessation products and nicotine replacement therapy (NRT) products that are expanding the avenues for quitting smoking and overcoming nicotine addiction.


In 2020, North America took a leading position in the global smoking cessation and nicotine withdrawal market, with the United States offering significant revenue opportunities for market participants.


Europe is another lucrative market region. Over the years, the implementation of anti-smoking initiatives in certain areas and the rapid adoption of nicotine-containing smoking cessation products have created a significant source of revenue.


The Asia-Pacific region is witnessing a colossal market, and noteworthy is the incredible untapped avenue that manufacturers of NRT (nicotine replacement therapy) products are discovering in the region.


I am sorry, I cannot do that as the original text in unclear. Please provide me with the text you want me to translate.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK Tobacco and Vapes Bill Receives Royal Assent, Banning Tobacco Sales to People Born After 2008
UK Tobacco and Vapes Bill Receives Royal Assent, Banning Tobacco Sales to People Born After 2008
The UK government announced on April 29 that the Tobacco and Vapes Bill had received Royal Assent and become law. Under the new law, it is illegal to sell tobacco to anyone born on or after Jan. 1, 2009. The government said the law creates the UK’s first “smoke-free generation” and includes measures to ban the advertising and sponsorship of vapes and nicotine products, as well as powers to restrict packaging, branding and displays designed to appeal to children.
Apr.30 by 2FIRSTS.ai
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14
Pennsylvania to Publish Vape Manufacturer Directory by June 20
Pennsylvania to Publish Vape Manufacturer Directory by June 20
Now that Act 57 of 2025 is in effect, every manufacturer of nicotine-containing electronic cigarettes sold or offered for retail sale in Pennsylvania must be certified by the Pennsylvania Office of the Attorney General.
Apr.10 by 2FIRSTS.ai
IVG Adds Six New Flavours to Pro Range, Expanding Line-Up to 39
IVG Adds Six New Flavours to Pro Range, Expanding Line-Up to 39
IVG has added six new flavours to its Pro range, taking the total line-up to 39 flavours. The new additions are Cola Frost, Rainbow Burst, Pineapple Tropic, Blueberry Raspberry, Strawberry Raspberry Ice and Raspberry Cherry Blueberry. All six are available only in 20mg nicotine strength, with an RRP of £10.95 for a starter kit and £7.95 for a refill pod.
Apr.21 by 2FIRSTS.ai
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
Philip Morris Japan announced on April 23 at a product briefing that ZYN by IQOS, an oral tobacco pouch previously launched in selected areas, will expand sales in Tokyo. The company said the product will be released progressively from May 11 through IQOS shops, Lawson and other outlets in the city. The launch will include four flavors, each offered in Low and Medium intensity levels, for a total of eight products.
Apr.27 by 2FIRSTS.ai